Indian Immunologicals Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Indian Immunologicals Limited Pharmaceutical Export Portfolio Dataset — 3 Products, $29.1M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Indian Immunologicals Limited — Pharmaceutical Exporter Profile (2026) | 3 Products, $29.1M Trade | TransData Nexus

Indian Immunologicals Limited

Indian Pharmaceutical Exporter · Other Specialist · $29.1M Total Trade · DGFT Verified

Indian Immunologicals Limited is an Indian pharmaceutical exporter with a total trade value of $29.1M across 3 products in 3 therapeutic categories. Based on 581 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Vaccine ($20.1M), Syringe ($8.3M), Extract ($600.0K).

Indian Immunologicals Limited — Export Portfolio & Destination Treemap

Indian Immunologicals Limited pharmaceutical export portfolio — 3 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is Indian Immunologicals Limited? — Company Overview & Market Position

Indian Immunologicals Limited (IIL) is a prominent biotechnology company based in Hyderabad, Telangana, India. Established in 1982 by the National Dairy Development Board (NDDB), IIL was incorporated as a public limited company in 1999 under the Corporate Identification Number (CIN) U72200TG1999PLC032666. The company specializes in the development and manufacturing of vaccines and other immunobiological products, serving both human and veterinary sectors. IIL's product portfolio includes over 150 items, with a significant presence in the Indian market and exports to more than 50 countries.

As a subsidiary of the NDDB, IIL operates with a mission to make biotechnology in healthcare affordable and accessible. The company's authorized capital is ₹400 crore, with a paid-up capital of ₹54 crore. IIL employs between 1,000 and 5,000 individuals, reflecting its substantial operational scale. The company's official website is www.indimmune.com.

What Does Indian Immunologicals Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Vaccine$20.1M 2

Product Portfolio — Top 3 by Export Value

Indian Immunologicals Limited exports 3 pharmaceutical products across 3 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Vaccine	Other	$20.1M	403	1.9%	6
2	Syringe	Medical Devices & Diagnostics	$8.3M	166	4.4%	3
3	Extract	Ayurvedic & Herbal Products	$600.0K	12	4.9%	5

Indian Immunologicals Limited exports 3 pharmaceutical products across 3 therapeutic categories with a total export value of $29.1M. The top category is Other (69.4% of portfolio), followed by Medical Devices & Diagnostics (28.6%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Indian Immunologicals Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

IIL operates multiple manufacturing facilities across India, each specializing in different aspects of vaccine production. The Gachibowli-Hyderabad facility is dedicated to the production of vaccines, while the Karakapatla-Hyderabad facility focuses on animal health formulations and human vaccines. Additionally, IIL has a facility in Ooty, Tamil Nadu, which exclusively produces the human anti-rabies vaccine, "Abhayrab." These facilities are equipped with state-of-the-art technology and adhere to stringent quality control measures to ensure the safety and efficacy of their products.

3Key Leadership

The leadership team at Indian Immunologicals Limited is headed by Managing Director Dr. K. Anand Kumar, who has been instrumental in steering the company's strategic direction and growth. The Chief Financial Officer (CFO) is G. Rajasekhar, responsible for overseeing the company's financial operations. Other key executives include Vice President & Head of R&D Rajendra Lingala, Vice President of Human Resources Mohan Rao, and Head of Marketing HR & L&D Narendra Agrawal. These leaders collectively contribute to IIL's mission of providing affordable and accessible biotechnology solutions in healthcare.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Indian Immunologicals Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Indian Immunologicals Limited has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained regulatory approvals for its products in these regions, ensuring compliance with international standards. For instance, IIL's facility in Ooty, Tamil Nadu, is WHO-GMP certified, indicating adherence to the World Health Organization's Good Manufacturing Practices. This certification facilitates the export of IIL's products to various countries, including those in the European Union and other regulated markets. Additionally, IIL's subsidiary, Pristine Biologicals Ltd in New Zealand, is involved in the production of serum used in the manufacture of vaccines, further expanding its international footprint.

2Emerging Markets

IIL has strategically expanded its reach into emerging markets across Africa, Latin America, and Southeast Asia. The company's products are exported to more than 50 countries, with a focus on regions such as the Middle East, Asia, Africa, and Central and Latin America. The World Health Organization's prequalification of IIL's products has been instrumental in facilitating access to these markets, as it ensures that the company's vaccines meet international standards of quality, safety, and efficacy. This prequalification is a critical factor in gaining acceptance and trust in emerging markets, where regulatory scrutiny is stringent.

Indian Immunologicals Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Indian Immunologicals Limited has made significant strides in the U.S. market, with its products being registered with the U.S. Food and Drug Administration (FDA). The company's facilities adhere to FDA standards, ensuring that its products meet the rigorous requirements for safety and efficacy. IIL has also filed Abbreviated New Drug Applications (ANDAs) and Drug Master Files (DMFs) with the FDA, facilitating the approval process for its products in the U.S. market. The company's commitment to quality is further demonstrated by its inspection history, which reflects compliance with FDA regulations. These efforts underscore IIL's dedication to expanding its presence in the U.S. and other regulated markets.

2WHO & EU GMP

Indian Immunologicals Limited's commitment to quality is evident through its adherence to international standards. The company's facilities, including the one in Ooty, Tamil Nadu, are WHO-GMP certified, indicating compliance with the World Health Organization's Good Manufacturing Practices. This certification is crucial for exporting products to the European Union, as it ensures that IIL's vaccines meet the stringent quality standards required by the European Medicines Agency (EMA). Additionally, IIL's products are prequalified by the WHO, further facilitating access to global markets.

Indian Immunologicals Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Indian Immunologicals Limited operates in a competitive landscape with several key players in the vaccine manufacturing sector. In the Indian market, IIL faces competition from companies such as Serum Institute of India and Bharat Biotech, which also have significant market shares in vaccine production. Globally, IIL competes with multinational corporations like GlaxoSmithKline and Sanofi Pasteur. Despite the competition, IIL has managed to secure a substantial market share in various segments, including pediatric and rabies vaccines, by focusing on quality, affordability, and accessibility. The company's strategic partnerships and adherence to international standards have further bolstered its position in the market.

2Key Differentiators

Indian Immunologicals Limited distinguishes itself through several key differentiators:

Affordability and Accessibility: IIL's mission to make biotechnology in healthcare affordable and accessible has led to the development of cost-effective vaccines, particularly for underserved populations.

Regulatory Compliance: The company's adherence to international standards, including WHO-GMP certification and WHO prequalification, ensures that its products meet global quality benchmarks.

Buyer Due Diligence Brief — Evaluating Indian Immunologicals Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Indian Immunologicals Limited has demonstrated a strong track record as a supplier of vaccines and immunobiologicals. The company's export volume of $29.1 million USD across 581 shipments indicates a consistent and reliable supply

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — Indian Immunologicals Limited

How many pharmaceutical products does Indian Immunologicals Limited export from India?

Indian Immunologicals Limited exports 3 pharmaceutical products across 3 therapeutic categories. The top exports are Vaccine ($20.1M), Syringe ($8.3M), Extract ($600.0K). Total export value is $29.1M.

What is Indian Immunologicals Limited's total pharmaceutical export value?

Indian Immunologicals Limited's total pharmaceutical export value is $29.1M, based on 581 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Indian Immunologicals Limited cover?

Indian Immunologicals Limited exports across 3 therapeutic categories. The largest are Other (69.4%, 1 products), Medical Devices & Diagnostics (28.6%, 1 products), Ayurvedic & Herbal Products (2.1%, 1 products).

Get Full Indian Immunologicals Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.